View in EDS HTML Full Text PDF Full Text

Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.

Saved in:
Bibliographic Details
Title: Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Authors: Ngo HX; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA., Xu AY; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.; Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA., Velásquez GE; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA.; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA., Zhang N; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA., Chang VK; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA., Kurbatova EV; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Whitworth WC; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Sizemore E; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Bryant K; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Carr W; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Weiner M; University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System, San Antonio, Texas, USA., Dooley KE; Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Engle M; University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System, San Antonio, Texas, USA., Dorman SE; Medical University of South Carolina, Charleston, South Carolina, USA., Nahid P; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA., Swindells S; University of Nebraska Medical Center, Omaha, Nebraska, USA., Chaisson RE; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Nsubuga P; Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda., Lourens M; TASK Applied Science CRS, Brooklyn Chest Hospital, Bellville, South Africa., Dawson R; Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Savic RM; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA.
Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1680-1689.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38462673
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ngo+HX%22">Ngo HX</searchLink>; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Xu+AY%22">Xu AY</searchLink>; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.; Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Velásquez+GE%22">Velásquez GE</searchLink>; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA.; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+N%22">Zhang N</searchLink>; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Chang+VK%22">Chang VK</searchLink>; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Kurbatova+EV%22">Kurbatova EV</searchLink>; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.<br /><searchLink fieldCode="AU" term="%22Whitworth+WC%22">Whitworth WC</searchLink>; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.<br /><searchLink fieldCode="AU" term="%22Sizemore+E%22">Sizemore E</searchLink>; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.<br /><searchLink fieldCode="AU" term="%22Bryant+K%22">Bryant K</searchLink>; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.<br /><searchLink fieldCode="AU" term="%22Carr+W%22">Carr W</searchLink>; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.<br /><searchLink fieldCode="AU" term="%22Weiner+M%22">Weiner M</searchLink>; University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System, San Antonio, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Dooley+KE%22">Dooley KE</searchLink>; Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Engle+M%22">Engle M</searchLink>; University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System, San Antonio, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Dorman+SE%22">Dorman SE</searchLink>; Medical University of South Carolina, Charleston, South Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Nahid+P%22">Nahid P</searchLink>; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Swindells+S%22">Swindells S</searchLink>; University of Nebraska Medical Center, Omaha, Nebraska, USA.<br /><searchLink fieldCode="AU" term="%22Chaisson+RE%22">Chaisson RE</searchLink>; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Nsubuga+P%22">Nsubuga P</searchLink>; Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.<br /><searchLink fieldCode="AU" term="%22Lourens+M%22">Lourens M</searchLink>; TASK Applied Science CRS, Brooklyn Chest Hospital, Bellville, South Africa.<br /><searchLink fieldCode="AU" term="%22Dawson+R%22">Dawson R</searchLink>; Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.<br /><searchLink fieldCode="AU" term="%22Savic+RM%22">Savic RM</searchLink>; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229203213%22">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</searchLink> [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1680-1689.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9203213 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1537-6591 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210584838%22">10584838 </searchLink><i>NLM ISO Abbreviation: </i>Clin Infect Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38462673
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/cid/ciae119
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1680
    Titles:
      – TitleFull: Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ngo HX
      – PersonEntity:
          Name:
            NameFull: Xu AY
      – PersonEntity:
          Name:
            NameFull: Velásquez GE
      – PersonEntity:
          Name:
            NameFull: Zhang N
      – PersonEntity:
          Name:
            NameFull: Chang VK
      – PersonEntity:
          Name:
            NameFull: Kurbatova EV
      – PersonEntity:
          Name:
            NameFull: Whitworth WC
      – PersonEntity:
          Name:
            NameFull: Sizemore E
      – PersonEntity:
          Name:
            NameFull: Bryant K
      – PersonEntity:
          Name:
            NameFull: Carr W
      – PersonEntity:
          Name:
            NameFull: Weiner M
      – PersonEntity:
          Name:
            NameFull: Dooley KE
      – PersonEntity:
          Name:
            NameFull: Engle M
      – PersonEntity:
          Name:
            NameFull: Dorman SE
      – PersonEntity:
          Name:
            NameFull: Nahid P
      – PersonEntity:
          Name:
            NameFull: Swindells S
      – PersonEntity:
          Name:
            NameFull: Chaisson RE
      – PersonEntity:
          Name:
            NameFull: Nsubuga P
      – PersonEntity:
          Name:
            NameFull: Lourens M
      – PersonEntity:
          Name:
            NameFull: Dawson R
      – PersonEntity:
          Name:
            NameFull: Savic RM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 06
              Text: 2024 Jun 14
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1537-6591
          Numbering:
            – Type: volume
              Value: 78
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
              Type: main
ResultId 1